Clinical Trials Browser

Has results × zanubrutinib × Lymphoid × Clear all

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03332017 2026-02-18

ROSEWOOD

Phase 2 Completed

217 enrolled 23 charts 1 FDA

Lymphoid

Lymphoma, Follicular

NCT04436107 2025-05-23

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Completed

66 enrolled 52 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03734016 2025-03-30

ALPINE

Phase 3 Completed

652 enrolled 27 charts 1 FDA

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02569476 2024-10-26

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Phase 1 Completed

119 enrolled 34 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT03053440 2024-10-26

ASPEN

Phase 3 Completed

201 enrolled 19 charts 1 FDA

Lymphoid

Waldenstrom Macroglobulinemia

NCT03145064 2024-10-26

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Phase 2 Completed

41 enrolled 15 charts

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03206918 2024-10-26

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Completed

91 enrolled 14 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03206970 2024-10-26

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Phase 2 Completed

86 enrolled 16 charts 1 FDA

Lymphoid

Lymphoma, Mantle-Cell

NCT03332173 2024-10-26

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Phase 2 Completed

44 enrolled 13 charts

Lymphoid

Waldenstrom Macroglobulinemia

NCT03520920 2024-10-26

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Phase 2 Completed

41 enrolled 25 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03846427 2024-10-26

MAGNOLIA

Phase 2 Completed

68 enrolled 28 charts 1 FDA

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT04551963 2024-10-26

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Phase 1 Completed

26 enrolled 20 charts

Lymphoid

B-cell Malignancies

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Phase 1 Completed

75 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence

NCT02343120 2022-04-28

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Phase 1/2 Completed

385 enrolled 29 charts 2 FDA

Lymphoid

B-cell Malignancies

Clinical Trials

SEQUOIA

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

ROSEWOOD

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ALPINE

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

ASPEN

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

MAGNOLIA

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies